PDZ domain containing ring finger 4Genealiases: LNX4 · SAMCAP3L
Q-omics provides the consensus-scored PDZRN4 profile across patient tissues and cancer cell-line models. PDZRN4 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, PDZRN4 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, PDZRN4 RNA expression shows 18,958 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight THCA, COAD, and GBM as cancer lineages where PDZRN4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDZRN4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDZRN4 survival associations across molecular data types. PDZRN4 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDZRN4 RNA expression–survival associations across cancer types. High PDZRN4 expression shows unfavorable associations in BLCA, but favorable associations in THCA, KIRC, HNSC, ESCA and BRCA. The THCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for PDZRN4 RNA expression.
This table summarizes PDZRN4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PDZRN4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDZRN4 shows lower tumor expression in COAD, KIRC, BLCA, KIRP, UCEC and LUAD. The COAD box plot shows higher PDZRN4 RNA expression in normal versus tumor tissue (log2 FC = −2.273, t-test p < 0.001).
This table shows molecular features associated with PDZRN4 in patient tissues and cancer cell lines. In patient samples, PDZRN4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PDZRN4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
